Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Poster Schedule
Home
Poster Schedule
All Days
Mon, Aug 26
Tue, Aug 27
Wed, Aug 28
Poster Schedule
Type here to filter the list
Tuesday, August 27, 2024
8:00 AM – 6:00 PM
CEST
(001) A Novel Methodology for Assessing Response to Lymphoma Treatment using Real World Data – the Real-World Lugano (rwLugano) Study
Favorite
8:00 AM – 6:00 PM
CEST
(002) A Quantitative Bias Analysis to Assess the Impact of Tumor Selection on Linear Growth in Observational Research: a Case Study in Renal Cancer.
Favorite
8:00 AM – 6:00 PM
CEST
(003) Age and sex-specific incidence of fracture events among persons with chronic lymphocytic leukemia
Favorite
8:00 AM – 6:00 PM
CEST
(004) Antidepressant use and depressive symptoms in cancer survivors: a Danish population-based study
Favorite
8:00 AM – 6:00 PM
CEST
(005) Assessment of the potential risk of seizure among patients with prostate cancer treated with enzalutamide in China: a non-interventional study
Favorite
8:00 AM – 6:00 PM
CEST
(006) Cancer treatment and the risk of acute kidney injury
Favorite
8:00 AM – 6:00 PM
CEST
(007) Beyond external control arms: utility of real-world data in oncology regulatory applications
Favorite
8:00 AM – 6:00 PM
CEST
(008) Breast cancer incidence by subtypes - a Danish register-based study from 2012 to 2022.
Favorite
8:00 AM – 6:00 PM
CEST
(009) Breast cancer recurrence due to avoidable drug-drug interactions? Developing a protocol for a target trial in women with breast cancer who concurrently use tamoxifen and antidepressants
Favorite
8:00 AM – 6:00 PM
CEST
(010) Cardiotoxic Cancer Treatment in Screen-Detected Versus Non-Screen-Detected Breast Cancer Patients: A Study Based on German Claims Data
Favorite
8:00 AM – 6:00 PM
CEST
(011) Characteristics and treatment sequences of patients with KRAS G12C, other KRAS and KRAS-wild-type advanced or metastatic (AM) Non-Small Cell Lung Cancer (NSCLC) in the French ESME cohort
Favorite
8:00 AM – 6:00 PM
CEST
(012) Characterization of Novel Longitudinal Oncology Real World Datasets in Germany and UK
Favorite
8:00 AM – 6:00 PM
CEST
(013) Clinical Features Associated with Disease Response Classification in Lymphoma: A Comparison of Data from Manual Chart Review and Blinded Independent Central Review
Favorite
8:00 AM – 6:00 PM
CEST
(014) Current Trends in the Therapeutic Management of Metastatic Prostate Cancer in Clinical Practice
Favorite
8:00 AM – 6:00 PM
CEST
(015) Discordance between clinical and pathological stage in non-small cell lung cancer patients in China
Favorite
8:00 AM – 6:00 PM
CEST
(016) Empirical Estimation of Hepatocellular Carcinoma Prevalence in Saudi Arabia: A Gender and Age Group Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(017) Feasibility of Using Deidentified Positron Emission Tomography–Computed Tomography (PET-CT) Scans to Support a Blinded Independent Central Review for Lymphoma Treatment Response Assessment using Real-World Data
Favorite
8:00 AM – 6:00 PM
CEST
(019) Incidence, Treatment Pattern, and Implications of Chemotherapy-Related Anemia in Patients with Solid Tumors in China: A Multicenter Retrospective Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(020) Incremental Burden of Comorbidity on Health-Related Quality of Life in Patients with Prostate Cancer
Favorite
8:00 AM – 6:00 PM
CEST
(021) Ischemic Cardiotoxicity of Aromatase Inhibitors in Postmenopausal Women with Early Breast Cancer: an Analysis of Real-World Data
Favorite
8:00 AM – 6:00 PM
CEST
(022) Machine Learning and Deep Learning Techniques for the Survival Prediction of Oropharyngeal Squamous Cell Carcinoma: Ahead of the Pack
Favorite
8:00 AM – 6:00 PM
CEST
(023) Neutropenia among patients with prostate cancer: Analysis of four US real world databases
Favorite
8:00 AM – 6:00 PM
CEST
(024) Performance of ChatGPT-3.5, ChatGPT-4, Microsoft Copilot, and Google Bard To Identify Correct Information for Lung Cancer
Favorite
8:00 AM – 6:00 PM
CEST
(025) Phenotype Development and Characterization of Patients with Prostate Cancer in Varying Disease Phases Using Real-World Data
Favorite
8:00 AM – 6:00 PM
CEST
(026) Real-world effectiveness of oral novel hormonal agents in patients with advanced prostate cancer: a head-to-head comparison using longitudinal, territory-wide electronic medical records
Favorite
8:00 AM – 6:00 PM
CEST
(027) Representativeness of race, ethnicity and social determinants of health in patients with advanced non-small cell lung cancer via linkage of real-world electronic health records, administrative claims, and consumer financial data
Favorite
8:00 AM – 6:00 PM
CEST
(028) Results from an analysis of data from the US SEER registries to estimate the prevalence of gastroenteropancreatic neuroendocrine tumors in the US, in the context of limited available evidence for regulatory discussions
Favorite
8:00 AM – 6:00 PM
CEST
(029) Risk factors for malignant transformation of oral epithelial dysplasia: a systematic review and meta-regression analysis
Favorite
8:00 AM – 6:00 PM
CEST
(030) The impact of Body Mass Index on colorectal cancer prognosis. A population-based cohort study in Denmark.
Favorite
8:00 AM – 6:00 PM
CEST
(031) The relation between tamoxifen metabolism and time to discontinuation: A Bayesian pathway analysis in premenopausal breast cancer patients
Favorite
8:00 AM – 6:00 PM
CEST
(032) Update on malignant transformation rate of oral epithelial dysplasia: a systematic review.
Favorite
8:00 AM – 6:00 PM
CEST
(033) US and Global Cutaneous Melanoma Burden: An Updated Epidemiology Assessment
Favorite
8:00 AM – 6:00 PM
CEST
(034) Vascular Endothelial Growth Factor Pathway Inhibitors and the Risk of Aortic Aneurysm and Aortic Dissection: A Nested Case-Control Study
Favorite
8:00 AM – 6:00 PM
CEST
(035) Assessing the utility of claims for haemoglobin A1c performance measures in characterizing glycemic control in older adult Medicare beneficiaries with diabetes.
Favorite
8:00 AM – 6:00 PM
CEST
(036) Association of educational level with clinical presentation and pharmacological treatment in 10,020 individuals with recently diagnosed type 2 diabetes
Favorite
8:00 AM – 6:00 PM
CEST
(037) Association of multimorbidity intervals with the risk of mortality among people living with diabetes: a territory-wide nested case-control study
Favorite
8:00 AM – 6:00 PM
CEST
(038) Cardiovascular Risk of Hormone Replacement Therapy in Menopausal Women with Diabetes: A Systematic Review and Meta-Analysis of Clinical Trials and Observational Studies
Favorite
8:00 AM – 6:00 PM
CEST
(039) Comparative Analysis of Potential Misuse between Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): Insights from FDA Adverse Event Reporting System (FAERS) Data
Favorite
8:00 AM – 6:00 PM
CEST
(040) Comparative Effectiveness of Anti-TNF Therapy and Vedolizumab in Crohn's Disease Patients
Favorite
8:00 AM – 6:00 PM
CEST
(041) Comparative Protective Effect on Alzheimer Disease between GLP1-RA and SGLT2 Inhibitors
Favorite
8:00 AM – 6:00 PM
CEST
(042) Comparative risk of lactic acidosis associated with initiation of metformin among patients with and without renal impairment
Favorite
8:00 AM – 6:00 PM
CEST
(043) Concomitant Use of Sulfonylurea and Amiodarone Associated with the Risk of Severe Hypoglycemia
Favorite
8:00 AM – 6:00 PM
CEST
(044) Dipeptidyl Peptidase-4 Inhibitors Use and Risk of Fracture in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Real-World Data
Favorite
8:00 AM – 6:00 PM
CEST
(045) Effect of COVID-19 restrictions on insulin consumption in Turkey: Results from Changes in Nationwide Drug Consumption During the Pandemic Study
Favorite
8:00 AM – 6:00 PM
CEST
(046) Effect of SGLT2 Inhibitors on Decreasing the Risk of Depression in Patients with Diabetes: A Nationwide Active-Comparator Cohort Study in Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(047) Efficacy and Safety of Luseogliflozin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(048) Exploring early signals for gliptins and gliflozins: A pharmacovigilance study on recent oral antidiabetic groups in Spain.
Favorite
8:00 AM – 6:00 PM
CEST
(049) Hypoglycaemia Risk and Medication De-intensification in Diabetes Patients: A Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(050) Identifying Prediabetes Patients Using Administrative Claims Linked with Lab Data to Assess Progression To Type 2 Diabetes and Treatment Initiation Patterns
Favorite
8:00 AM – 6:00 PM
CEST
(051) Incidence of Diabetic Ketoacidosis in Dapagliflozin Users vs. SGLT2i Non-users with Type 1 Diabetes Mellitus using a Japanese Claims Database
Favorite
8:00 AM – 6:00 PM
CEST
(052) Incretin-Based Drugs and the Incidence of Endometrial Cancer Among Patients with Type 2 Diabetes
Favorite
8:00 AM – 6:00 PM
CEST
(053) Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: A nationwide cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(054) Initiation of SGLT2i vs GLP1-RA and the Risk of Acute Kidney Injury in Persons with Type 2 Diabetes Mellitus
Favorite
8:00 AM – 6:00 PM
CEST
(055) Insulin Consumption Trends in Greece: A Retrospective Analysis of Diabetes consumption based on EOPPY Dataset (2015-2020)
Favorite
8:00 AM – 6:00 PM
CEST
(056) Investigating ethnic differences in the comparative effectiveness of classes of second-line antidiabetic medications at preventing cardiovascular outcomes.
Favorite
8:00 AM – 6:00 PM
CEST
(057) Methods for Extrapolating Findings from Randomized Clinical Trials using Real-World-Data
Favorite
8:00 AM – 6:00 PM
CEST
(058) Migration Background and HbA1c Checks and Balances: A Large Routine Care Data Study in the Netherlands
Favorite
8:00 AM – 6:00 PM
CEST
(059) Novel Glucose-lowering Drugs and Incident Dementia Among Patients With Type 2 Diabetes and Comorbid Mental Disorders: A Population-based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(060) Predicting Insulin Consumption in Relation to Diabetes: A Pharmacoepidemiological Analysis of the EOPYY Dataset in Greece (2015-2020)
Favorite
8:00 AM – 6:00 PM
CEST
(061) Predictive Model for Sight-Threatening Diabetic Retinopathy in People with Type 2 Diabetes Mellitus
Favorite
8:00 AM – 6:00 PM
CEST
(062) Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary practice
Favorite
8:00 AM – 6:00 PM
CEST
(063) Psychometric properties of the Treatment Satisfaction with Medicine Questionnaire (SATMED-Q) in Indonesian patients with type 2 diabetes
Favorite
8:00 AM – 6:00 PM
CEST
(064) Real-world evidence generation methods used to estimate fracture risk with drugs to treat type 2 diabetes mellitus: a scoping review
Favorite
8:00 AM – 6:00 PM
CEST
(065) Relationship between Anti-diabetic Medication Use and Glycaemic Control in an Asian Cohort with Diabetes in Singapore
Favorite
8:00 AM – 6:00 PM
CEST
(066) Risk of Acute Kidney Injury in Dapagliflozin Users with Type 2 Diabetes: A Nationwide Cohort Study with Propensity Score Matching
Favorite
8:00 AM – 6:00 PM
CEST
(067) Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors in the FDA Sentinel System
Favorite
8:00 AM – 6:00 PM
CEST
(068) Risk of New-onset Type 2 Diabetes Mellitus Associated with 5-Alpha Reductase Inhibitors: A Nationwide Population-Based Study
Favorite
8:00 AM – 6:00 PM
CEST
(069) Safety of concomitant use of antidiabetic drugs and oral anticoagulants: a systematic review of observational studies
Favorite
8:00 AM – 6:00 PM
CEST
(070) Semaglutide injection with type 2 diabetes indication – User trends and Off-label Prescribing for Weight Loss from 2018 through 2023 in Denmark
Favorite
8:00 AM – 6:00 PM
CEST
(071) Sex Disparities in Medication Changes After Metformin Initiation are Associated With Small, Clinically Non-Relevant, Sex Differences in HbA1c Levels During Follow-up
Favorite
8:00 AM – 6:00 PM
CEST
(072) Temporal Trends in the Dispensing Patterns of Semaglutide and Dulaglutide in Ireland from 2018-2023
Favorite
8:00 AM – 6:00 PM
CEST
(073) The Health Status & Related Quality of Life among Patients with T2DM using EQ-5D-5L Instrument at a Tertiary Healthcare Facility in Nigeria.
Favorite
8:00 AM – 6:00 PM
CEST
(074) The Prevalence of Depression among Patients with Type 2 Diabetes: An Umbrella Review
Favorite
8:00 AM – 6:00 PM
CEST
(075) The Use of Potentially Interacting Supplement–Drug Pairs in Adults with Type 2 Diabetes: A Large Population-Based Cohort Study in the UK Biobank
Favorite
8:00 AM – 6:00 PM
CEST
(076) Treatment Modification Patterns of Glucose-Lowering Agents in Saudi Arabia: A Retrospective Real-world Data Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(077) Trends in use of diabetes drugs in Sweden 1977–2022: A cross-sectional study
Favorite
8:00 AM – 6:00 PM
CEST
(078) Two-arm Study on Deprescribing of Antihyperglycemic Agents Causing Hypoglycaemia Among Geriatric Patients
Favorite
8:00 AM – 6:00 PM
CEST
(079) Use of new technologies and well-being in adults with type 1 diabetes mellitus
Favorite
8:00 AM – 6:00 PM
CEST
(080) Utilization of sodium-glucose cotransporter 2 inhibitors post-regulatory approval as an adjunctive therapy for type 1 diabetes mellitus: Insight from real-world experience in Japan
Favorite
8:00 AM – 6:00 PM
CEST
(081) Visit-to-visit lipid variability and risk of renal outcomes among patients with type 2 diabetes
Favorite
8:00 AM – 6:00 PM
CEST
(082) Vitamin D and the Microvascular Complications of Type 2 Diabetes in India: A Case-Control Study
Favorite
8:00 AM – 6:00 PM
CEST
(083) A Case-control Study On Polypharmacy And Co-medications in Alzheimer’s Disease
Favorite
8:00 AM – 6:00 PM
CEST
(084) A dynamic fall risk prediction and monitoring tool in aged care using routinely collected electronic health data: Development and internal validation of the FRIPAC tool
Favorite
8:00 AM – 6:00 PM
CEST
(085) Adherence to Hypertension Treatment Among the Older Individuals: Do Depression and Anxiety Influence Adherence Trajectories?
Favorite
8:00 AM – 6:00 PM
CEST
(086) Adverse Drug reactions in an Ageing PopulaTion rIsk Prediction Tool (ADAPtIP): the development of a model for predicting adverse drug reactions in older patients admitted to hospital
Favorite
8:00 AM – 6:00 PM
CEST
(087) Anticoagulant Deprescribing After An Emergency Department Visit Due To Gastrointestinal Bleeding Among Older Patients Using Multiple Medications
Favorite
8:00 AM – 6:00 PM
CEST
(088) Antidepressants and Risk of Orthostatic Hypotension: a Self-Controlled Case Series Study
Favorite
8:00 AM – 6:00 PM
CEST
(089) Are drugs discontinued after hospital-based medication reviews in older adults? A nationwide register-based study in 2022
Favorite
8:00 AM – 6:00 PM
CEST
(090) Association between Recently Raised Anticholinergic Burden and Risk of Delirium – A case-case-time-control Study
Favorite
8:00 AM – 6:00 PM
CEST
(091) Association between use of Furosemide and Risk of Parkinson’s disease
Favorite
8:00 AM – 6:00 PM
CEST
(092) Association of Systemic Anticholinergic Medication use and Accelerated Decrease in Lung function in Older adults.
Favorite
8:00 AM – 6:00 PM
CEST
(093) Associations between gender, race/ethnicity and age and the initiation of chronic high-risk medication in US older adults
Favorite
8:00 AM – 6:00 PM
CEST
(094) Brain Imaging In United States Veterans Before and After Establishing Criteria for Use of Anti-amyloid Therapy for Treatment of Mild Cognitive Impairment and Alzheimer’s Dementia
Favorite
8:00 AM – 6:00 PM
CEST
(095) Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort
Favorite
8:00 AM – 6:00 PM
CEST
(096) Comparing Dementia and Cognitive Impairment Risks in Older Type-2 Diabetic Patients: A Danish Register-Based Study on Dipeptidyl Peptidase-4 Inhibitors vs. Glucagon-like Peptide-1 Analogues
Favorite
8:00 AM – 6:00 PM
CEST
(097) Cost-Effectiveness of Lecanemab (Leqembi) for Individuals With Early-Stage Alzheimer’s Disease
Favorite
8:00 AM – 6:00 PM
CEST
(098) Dementia Medications and their Association with Pain Medication Use in Medicare Beneficiaries with Dementia and Chronic Pain
Favorite
8:00 AM – 6:00 PM
CEST
(099) Description of time trends in the of users of Janus kinase inhibitors in Sweden using a joinpoint regression approach
Favorite
8:00 AM – 6:00 PM
CEST
(100) Developing a novel claim-based algorithm to identify incident and prevalent dementia using Medicare claims of the Atherosclerosis Risk in Communities (ARIC) cohort
Favorite
8:00 AM – 6:00 PM
CEST
(101) Discontinuation of chronically used medication in routine clinical practice among Swedish older adults: A nationwide cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(102) Drug target Mendelian Randomisation vs regression methods: estimating causal effects of sclerostin inhibition on bone mineral density and fracture risk
Favorite
8:00 AM – 6:00 PM
CEST
(103) Effectiveness and Safety of Oral Anticoagulants among Long-term Nursing Home Residents with atrial fibrillation (AF) and Moderate to Severe Impairment in Functional Status
Favorite
8:00 AM – 6:00 PM
CEST
(104) Effectiveness of Gabapentinoids versus Muscle Relaxants on Opioid Discontinuation among Older Adults with Prolonged Opioid Use
Favorite
8:00 AM – 6:00 PM
CEST
(105) Effectiveness of Mono and Dual Antidementia Pharmacotherapy Among US Nursing Home Residents
Favorite
8:00 AM – 6:00 PM
CEST
(106) Epidemiological Landscape of Human Metapneumovirus Among Older Adults in High-Income Countries: Systematic Literature Review and Meta-Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(107) Estimating the Prevalence of Preclinical Alzheimer’s Disease with Subjective Cognitive Decline among US Adults
Favorite
8:00 AM – 6:00 PM
CEST
(108) Evaluating Caregiver Quality of Life, Indirect and Intangible Costs and their Association with Alzheimer’s Disease Severity in the US
Favorite
8:00 AM – 6:00 PM
CEST
(109) Evaluating Drug Use Patterns in Hospitalized Elderly: A Study on Polypharmacy and Compliance
Favorite
8:00 AM – 6:00 PM
CEST
(110) Evaluating Lecanemab Eligibility for Patients in Skilled Nursing Facilities with Alzheimer's Disease or Mild Cognitive Impairment
Favorite
8:00 AM – 6:00 PM
CEST
(111) Evaluation of QT Prolonging Drug Use Among Elderly with Psychiatric Disorders in India using Beers Criteria(2019) and STOPP Criteria(2015)
Favorite
8:00 AM – 6:00 PM
CEST
(112) Exploring Anticholinergic Co-Medication Networks in HIV and Frailty: An Exploratory Random Graph Modelling Approach
Favorite
8:00 AM – 6:00 PM
CEST
(113) Exploring the Association Between Intention and Action in Deprescribing
Favorite
8:00 AM – 6:00 PM
CEST
(114) Exploring the Feasibility and added Value of a Comorbidity Index Score in a Pharmacovigilance Database
Favorite
8:00 AM – 6:00 PM
CEST
(115) Factors associated with potentially inappropriate medicines use in older adults during the covid-19 pandemic in two Brazilian municipalities: a cross-sectional study
Favorite
8:00 AM – 6:00 PM
CEST
(116) Feasibility of a Federated Network Analysis Using Real-World Data Mapped to OMOP Common Data Model to Estimate Healthcare Resource Utilisation and Costs of Imminent Subsequent Fracture
Favorite
8:00 AM – 6:00 PM
CEST
(117) Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson’s Disease in U.S. Older Adults with Type 2 Diabetes: A Population-Based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(118) Glucagon-Like Peptide-1 Receptor Agonists and Risk of Suicide/Self-harm in U.S. Older Adults with Type 2 Diabetes: A Population-Based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(119) Glucose lowering medication utilization before and after entry into long-term care among older people with diabetes
Favorite
8:00 AM – 6:00 PM
CEST
(120) How much frequently are biological drugs used in patients over 65 years with immune-mediated inflammatory diseases through the Italian VALORE distributed database network
Favorite
8:00 AM – 6:00 PM
CEST
(121) Identifying Clustering of Clinic-level Prescribing Patterns for Patients with Differing Health Coverage in Primary Care in Ireland: a Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(122) Implementation of a cluster-based High-Performance Computing solution for logistic regression, random forest and XGBoost algorithms to predict memory impairment in older adults
Favorite
8:00 AM – 6:00 PM
CEST
(123) Improving Prescription Appropriateness of Proton Pump Inhibitors: The LAPTOP-PPI Study
Favorite
8:00 AM – 6:00 PM
CEST
(124) Incidence and Complications of Rectopexy in the United Kingdom and United States, 2013-2022.
Favorite
8:00 AM – 6:00 PM
CEST
(125) Low-Dose Aspirin and Risk of Anemia in Older Adults: Insights from a Danish Register-based Study
Favorite
8:00 AM – 6:00 PM
CEST
(126) Medicare Annual Wellness Visits and Incident Alzheimer’s Disease Diagnosis among a Medicare Advantage Population, 2016-2022
Favorite
8:00 AM – 6:00 PM
CEST
(127) National trends in utilization of glucose lowering medications by older people with diabetes in long-term care facilities, 2009 to 2019
Favorite
8:00 AM – 6:00 PM
CEST
(128) Network Analysis of Chronic Medication Use in Older Adults Living with Dementia Prior to and Following Diagnosis: A Web-based Visualisation Tool
Favorite
8:00 AM – 6:00 PM
CEST
(129) Older US adults refilling potentially inappropriate medications after hip fracture
Favorite
8:00 AM – 6:00 PM
CEST
(130) PARTNER pilot study: Interprofessional clinical pathway to patient-oriented deprescribing of psychotropic and anticholinergic medications in elderly patients with polypharmacy
Favorite
8:00 AM – 6:00 PM
CEST
(131) Pharmacological treatments and medication-related problems in nursing homes in Catalonia: The impact of a multidisciplinary team intervention
Favorite
8:00 AM – 6:00 PM
CEST
(132) Polypharmacy and Potentially Inadequate Medication in Older Adults: Results from the German National Cohort (NAKO) Baseline.
Favorite
8:00 AM – 6:00 PM
CEST
(133) Prescription Sequence Symmetry Analysis to Identify Prescription Cascades for Dementia Drug Treatments in the United Kingdom
Favorite
8:00 AM – 6:00 PM
CEST
(134) Prevalence and factors associated with polypharmacy and self-medication among the elderly population residing in urban Indian communities
Favorite
8:00 AM – 6:00 PM
CEST
(135) Primary Care Resource Utilisation and Costs of Fragility Fractures in Postmenopausal Women in the UK Using CPRD Data Mapped to OMOP Common Data Model
Favorite
8:00 AM – 6:00 PM
CEST
(136) Regional Variations Between Drug Treatment Recommendations for Insomnia in Older People in Sweden
Favorite
8:00 AM – 6:00 PM
CEST
(137) Risk of sarcopenia following long-term statin use in community-dwelling middle-aged and older adults in Japan: evidence from a 10-year population-based cohort study using propensity score matching and overlap weighting
Favorite
8:00 AM – 6:00 PM
CEST
(138) Risk of ventricular arrhythmias or sudden cardiac death and acetylcholinesterase inhibitors among older adults with dementia
Favorite
8:00 AM – 6:00 PM
CEST
(139) Risk Prediction Models for Adverse Drug Reactions and Adverse Drug Events in Older Adults – A Systematic Review
Favorite
8:00 AM – 6:00 PM
CEST
(140) SGLT2 inhibitors and Parkinson’s disease (PD) risk in older populations with type 2 diabetes (T2D)
Favorite
8:00 AM – 6:00 PM
CEST
(141) Spousal bereavement and four-year trajectories of medication use: a nationwide register-based study in Swedish older adults
Favorite
8:00 AM – 6:00 PM
CEST
(142) Telehealth's Impact in Alzheimer's Medication Management: A Real-World EMR Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(143) The prevalent new-user study design: a novel application to estimating the average treatment effect of statin discontinuation on mortality among traditional Medicare beneficiaries who discontinued statins
Favorite
8:00 AM – 6:00 PM
CEST
(144) Trends of the prevalence of polypharmacy and potentially inappropriate medications in people with dementia from 2006 to 2021 in Hong Kong
Favorite
8:00 AM – 6:00 PM
CEST
(145) Unraveling the use of diagnostic tests for mild cognitive impairment, Alzheimer’s disease, and other dementias: a real-world study
Favorite
8:00 AM – 6:00 PM
CEST
(146) Use of Immunomodulators/Biologics is protective against Major Adverse Cardiovascular Events in Medicare patients with Inflammatory Bowel Disease over use of 5-ASA alone.
Favorite
8:00 AM – 6:00 PM
CEST
(147) Which Medication Counting Method is Useful for Predicting Death and Institutionalization in Older Adults? A Population-Based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(148) Assessing Data Discontinuity: A Study of Atrial Fibrillation Recurrence Across Hospital Boundaries Using Tokenization
Favorite
8:00 AM – 6:00 PM
CEST
(149) Association of Global Evaluative Assessment of Robotic Skills (GEARS) Scores with Operative Time for Robotic Hysterectomy: a Retrospective Study
Favorite
8:00 AM – 6:00 PM
CEST
(150) Characterizing device and treatment of patients with deep dermal or full thickness thermal burns in the National Burn Registry between 2021-2023
Favorite
8:00 AM – 6:00 PM
CEST
(151) Clinical and Economic Outcomes of Cesarean Deliveries with Skin Closure through Conventional Sutures Plus Waterproof Wound Dressings versus 2-octyl Cyanoacrylate Plus Polymer Mesh Tape
Favorite
8:00 AM – 6:00 PM
CEST
(152) Determinants of Use of Minimally Invasive Robot-Assisted Surgery: a Cohort Study from the French Nationwide Claims Database
Favorite
8:00 AM – 6:00 PM
CEST
(153) Evaluation of the Adverse Effects of Family Planning Implants in Nigerian Women in Lagos State
Favorite
8:00 AM – 6:00 PM
CEST
(155) How much data are lost in longitudinal studies of medical devices using hospital databases? Hospital data linked with claims data for Atrial Fibrillation ablation treatment.
Favorite
8:00 AM – 6:00 PM
CEST
(156) How well does hospital billing data estimate readmissions and revision risks after spinal fusion surgery compared to hospital billing linked to claims data?
Favorite
8:00 AM – 6:00 PM
CEST
(157) Postoperative Clinical and Economic Outcomes of Patients with Reverse or Anatomic Total Shoulder Arthroplasty at One Year: A Retrospective, United States Hospital Billing Database Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(158) Predictors Of The Utilization Of Lung Cancer Screening With Low-Dose Computed Tomography (LDCT) In The United States (US) Commercially Insured Population
Favorite
8:00 AM – 6:00 PM
CEST
(159) Readmission Rates and Costs Associated with the Use of Enterprise 2 and Neuroform Atlas Stents for Unruptured Intracranial Aneurysms: A Comparative Real-World Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(160) Real-world data collection for medical device regulatory submissions: Considerations in epidemiology
Favorite
8:00 AM – 6:00 PM
CEST
(161) Risk of Thermal Burns in Electrosurgery: A U.S. cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(162) Switching and continuation patterns of consecutive IUD users - results from a large observational, real-world study in Europe (EURAS-LCS12)
Favorite
8:00 AM – 6:00 PM
CEST
(163) Trends in Adoption of Knotless Tissue Control Devices in Robotic Surgery: A Retrospective Database Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(164) Use of Real-World Data to Evaluate Overall Survival Following Robotic-Assisted Versus Non-Robotic Assisted Radical Prostatectomy
Favorite
8:00 AM – 6:00 PM
CEST
(165) A hypothetical case study describing different intercurrent events in an observational prospective study: Differential interpretation of results
Favorite
8:00 AM – 6:00 PM
CEST
(166) A Novel, Hypothesis-free Approach to Detecting Safety Signals by Clustering Distributed Representations of Adverse Events Based on Claims Databases
Favorite
8:00 AM – 6:00 PM
CEST
(167) A retrospective look at the efficiency of 100% source data verification and the possibilities presented by risk-based quality management in increasing monitoring efficiency while maintaining good data quality.
Favorite
8:00 AM – 6:00 PM
CEST
(168) A step-by-step guide for incorporating estimands in observational studies
Favorite
8:00 AM – 6:00 PM
CEST
(169) Application of the Target Trial Emulation Framework to External Comparator Studies
Favorite
8:00 AM – 6:00 PM
CEST
(170) Minimizing Confounding in Comparative Observational Studies with Time-To-Event Outcomes: An Extensive Comparison of Covariate Balancing Methods Using Monte Carlo Simulation
Favorite
8:00 AM – 6:00 PM
CEST
(171) Assessing the potential for sequential channeling bias for drugs with continuously expanded patient populations: an illustrative example using dupilumab
Favorite
8:00 AM – 6:00 PM
CEST
(172) Assessing the Use of the Estimand Framework in Recent Pharmacoepidemiologic Post-market Safety Studies
Favorite
8:00 AM – 6:00 PM
CEST
(173) Characterization of treatment and disease burden of patients with bipolar disorder using Observational Medical Outcomes Partnership (OMOP) mapped datasets
Favorite
8:00 AM – 6:00 PM
CEST
(174) Comparing publicly available methods for assessing covariate balance using standardized differences after implementation of weighting strategies
Favorite
8:00 AM – 6:00 PM
CEST
(177) Development and Clinical Validation of a Generative AI Assisted Medication-Indication Knowledge Base
Favorite
8:00 AM – 6:00 PM
CEST
(178) Enhancing Data Continuity: Tokenized Linkage Extends Patient Observations for Real World Evidence Generation - A Komodo Research Dataset Study
Favorite
8:00 AM – 6:00 PM
CEST
(179) Excluding or Censoring on Mediators and the Resulting Causal Estimands: An Example of Hormonal Contraceptives and Venous Thromboembolism Risk
Favorite
8:00 AM – 6:00 PM
CEST
(180) External Comparator Cohort studies – clarification of terminology
Favorite
8:00 AM – 6:00 PM
CEST
(181) External Comparators and Estimands
Favorite
8:00 AM – 6:00 PM
CEST
(182) Factors associated with Remote Recruiting in Patient Centered Outcomes Research Studies
Favorite
8:00 AM – 6:00 PM
CEST
(183) Feasibility of Constructing an External Control Arm with Real-World Data to Augment Subgroups in Cardiorenal Trials: A Matched Cohort Study Focusing on Trial Subgroups of Sodium-Glucose Cotransport 2 Inhibitor Users at Baseline
Favorite
8:00 AM – 6:00 PM
CEST
(184) Feasibility of the OMOP Common Data Model for German claims data
Favorite
8:00 AM – 6:00 PM
CEST
(185) Federated learning as a smart tool for data analysis in infectious disease research: a scoping review
Favorite
8:00 AM – 6:00 PM
CEST
(186) Flexible parametric survival models for simultaneous estimation on multiple timescales: an application using nationwide Swedish register data
Favorite
8:00 AM – 6:00 PM
CEST
(187) Identifying the average treatment effect in the treated: Illustration using the Northwest Germany Stroke Registry.
Favorite
8:00 AM – 6:00 PM
CEST
(188) Improved Prediction of Overall Survival Using Machine Learning Survival Models Incorporating Time-Dependent Features
Favorite
8:00 AM – 6:00 PM
CEST
(189) Improving the Role of External Control Arms in Early-Phase Single Arm Trials
Favorite
8:00 AM – 6:00 PM
CEST
(190) Investigation of inclusion and exclusion criteria in Alzheimer’s disease clinical trials on patient sample representation through natural language processing
Favorite
8:00 AM – 6:00 PM
CEST
(191) Landscape Assessment of Clone-Censor-Weight Methodology Application in Real-World Data Studies: A Scoping Review
Favorite
8:00 AM – 6:00 PM
CEST
(192) Line of therapy algorithm for real-world data analysis in multiple myeloma
Favorite
8:00 AM – 6:00 PM
CEST
(193) Medication Data in Research: Improving Completeness Using Rule-based Algorithms on Textual Variables
Favorite
8:00 AM – 6:00 PM
CEST
(194) Ontology-based Semantic Similarity Measures in Drug Safety: A Literature Review
Favorite
8:00 AM – 6:00 PM
CEST
(195) Optimal matching ratios for the analysis of time-to-event outcomes in matched cohort studies in EHR research: A simulation study
Favorite
8:00 AM – 6:00 PM
CEST
(196) PRE2DUP-R, open source program for assessment of PREscriptions to Drug Use Periods
Favorite
8:00 AM – 6:00 PM
CEST
(197) Predicting CRC Screening Uptake using Machine Learning and Ensemble Models
Favorite
8:00 AM – 6:00 PM
CEST
(198) Predicting survival using geriatric assessment (GA) in older adults with advanced cancer using least absolute selection and shrinkage operator (LASSO)
Favorite
8:00 AM – 6:00 PM
CEST
(199) Proof-of-concept for a UK federated data network using the OMOP common data model: the UK regulatory studyathon
Favorite
8:00 AM – 6:00 PM
CEST
(200) Scalable Natural Language Processing for Large-Scale Covariate Adjustment in Healthcare Database Studies
Favorite
8:00 AM – 6:00 PM
CEST
(201) Specifying the target trial reveals exceptions to commonly accepted rules of target trial emulation
Favorite
8:00 AM – 6:00 PM
CEST
(202) Systematic Definition Development of Variables of Interest for Studies Using Administrative Databases
Favorite
8:00 AM – 6:00 PM
CEST
(203) Testing machine learning prediction models to impute missing data in claims databases
Favorite
8:00 AM – 6:00 PM
CEST
(204) The Current Use of Single Arm Trials (SAT): A Targeted Literature Review
Favorite
8:00 AM – 6:00 PM
CEST
(205) There's something about Albumin: Applying the Roadmap for Causal Inference to Estimate the Effect of Albumin Levels on Pressure Injury Development in Hospital Settings
Favorite
8:00 AM – 6:00 PM
CEST
(206) Trials Replication through Observational study across OHDSI (TROY)
Favorite
8:00 AM – 6:00 PM
CEST
(207) Understanding the Utility of Historical Cohort Studies Via Retrospective Chart Review in Inflammatory Bowel Disease: A Review of Global Studies
Favorite
8:00 AM – 6:00 PM
CEST
(208) Using large language models with real world data to support regulatory decision-making for medicinal products: Are we on the road to regulatory convergence or chaos?
Favorite
8:00 AM – 6:00 PM
CEST
(209) What Exactly Does Clone-Censor-Weighting Estimate When Studying Treatment Initiation Windows, Anyway?
Favorite
8:00 AM – 6:00 PM
CEST
(210) Adjunctive treatments for depression: Delineating real-world treatment patterns
Favorite
8:00 AM – 6:00 PM
CEST
(211) Agomelatine and Inverse Risk of Hypertension, Diabetes and Hyperlipidemia: A Nationwide Active-comparator Study
Favorite
8:00 AM – 6:00 PM
CEST
(212) An Active Safety Surveillance Using Real-World Evidence (ASSURE) Approach to Pharmacovigilance Signal Evaluation: The case of methylphenidate and potential signal for obsessive-compulsive disorders
Favorite
8:00 AM – 6:00 PM
CEST
(213) An Assessment of Use and Emerging Safety of Esketamine Nasal Spray in the U.S., 2019-2023
Favorite
8:00 AM – 6:00 PM
CEST
(214) Characteristics and drug utilization patterns of patients with migraine initiating erenumab in Nordic countries
Favorite
8:00 AM – 6:00 PM
CEST
(215) Concurrent Use of Prescription Benzodiazepines and Cannabis in Prevalent Medical Cannabis Users with Mental Health Conditions: A Cross-Sectional Survey
Favorite
8:00 AM – 6:00 PM
CEST
(216) Deprescribing of antidepressants: Development of indicators of high-risk and overprescribing using the RAND/UCLA Appropriateness Method
Favorite
8:00 AM – 6:00 PM
CEST
(217) Effectiveness of low-dose amitriptyline and mirtazapine in insomnia disorder: a randomised, double-blind, placebo-controlled trial in general practice (the DREAMING study)
Favorite
8:00 AM – 6:00 PM
CEST
(218) Estimation of Daily Delta-9-Tetrahydrocannabinol Doses Among Participants in Florida's Medical Marijuana Use Registry: A Study on Trends and Patterns in Medical Cannabis Utilization
Favorite
8:00 AM – 6:00 PM
CEST
(219) Identification of migraine in electronic healthcare data sources: a headache for pharmacoepidemiologists – a systematic literature review
Favorite
8:00 AM – 6:00 PM
CEST
(220) Impact of deregulation of the Brazilian National Controlled Products Management System on antidepressants’ sales data
Favorite
8:00 AM – 6:00 PM
CEST
(221) Incidence of moderate and profound hyponatremia during treatment with selective serotonin reuptake inhibitors (SSRIs) – evidence from the Stockholm Sodium Cohort (SSC).
Favorite
8:00 AM – 6:00 PM
CEST
(222) Medically-attended cannabis-related disorders among U.S. Medicare beneficiaries, 2017–2022
Favorite
8:00 AM – 6:00 PM
CEST
(223) Modeling Medical, Prescription, Disability, and Absence Costs for Employees with Major Depressive Disorder (MDD): Using Shorter Pre-Index Time Periods for Charlson Comorbidity Indexes (CCI) and Smaller Sample Sizes
Favorite
8:00 AM – 6:00 PM
CEST
(224) Patient characteristics associated with new community prescription of benzodiazepine and z-drug hypnotics after critical illness in the UK, a retrospective cohort study.
Favorite
8:00 AM – 6:00 PM
CEST
(225) Peyronie´s disease and risk of depression. A nationwide 25-year cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(226) Prevalence and sociodemographic characteristics of people with prescription stimulant use disorder: results from the National Survey on Drug Use and Health, 2015-2019
Favorite
8:00 AM – 6:00 PM
CEST
(227) Risk assessment of decreased platelet count in patients prescribed antidepressants using the MID-NET in Japan
Favorite
8:00 AM – 6:00 PM
CEST
(228) Trends of Triptans Use in Hungary
Favorite
8:00 AM – 6:00 PM
CEST
(229) A national population cohort study of congenital abnormalities following SARS-CoV-2 infection and COVID-19 vaccination during pregnancy
Favorite
8:00 AM – 6:00 PM
CEST
(230) A Population-Based Cohort Study of Drug Exposures and Adverse Pregnancy Outcomes in China (DEEP): Rationale, Design, and Baseline Characteristics
Favorite
8:00 AM – 6:00 PM
CEST
(231) A Target Trial of Pre-conception Switch from a Legacy Medication to a New Medication – An Application to Antiretroviral Therapy and Birth Outcomes
Favorite
8:00 AM – 6:00 PM
CEST
(232) Addressing Over-Representation of Early Pregnancy Outcomes in Database Pregnancy Safety Studies
Favorite
8:00 AM – 6:00 PM
CEST
(233) Algorithms to identify major congenital malformations in routinely collected healthcare databases: A systematic literature review
Favorite
8:00 AM – 6:00 PM
CEST
(234) Analysis of Medicinal Product Utilization Data in the FDA Sentinel System to Inform the Development of a Pregnancy Safety Study Framework
Favorite
8:00 AM – 6:00 PM
CEST
(235) Analysis of Postapproval Pregnancy Safety Studies Associated with FDA Approved Products
Favorite
8:00 AM – 6:00 PM
CEST
(236) Apgar-5 scores variability and associated pregnancy outcomes among hospitalized women: Insights from national linked Brazilian secondary databases
Favorite
8:00 AM – 6:00 PM
CEST
(237) Application of a direct-to-participant EMR data collection platform for pregnancy registries
Favorite
8:00 AM – 6:00 PM
CEST
(238) Assessing the Credibility of Causal Effects: A Critical Analysis of Observational Studies on Pregnancy Drug Use and Congenital Malformations
Favorite
8:00 AM – 6:00 PM
CEST
(239) Association Between Levothyroxine Supplementation for Hypothyroidism in Late Pregnancy and Risk of Preterm Delivery
Favorite
8:00 AM – 6:00 PM
CEST
(240) Association Between Maternal Anticholinergic Burden During Pregnancy and the Risk of Autism Spectrum Disorder: A Population-Based Cohort Study in Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(241) Association of First Trimester Macrolide Use With Congenital Malformations in the Offspring
Favorite
8:00 AM – 6:00 PM
CEST
(242) Association of prenatal antiseizure medication exposure with risk of neurodevelopmental disorders in children
Favorite
8:00 AM – 6:00 PM
CEST
(243) Associations Between Chronic Diseases and Treatments During Lactation and Maternal Mental Health
Favorite
8:00 AM – 6:00 PM
CEST
(244) Associations between diphenhydramine and specific birth defects stratified by imputed indication, National Birth Defects Prevention Study and Birth Defects Study to Evaluate Pregnancy exposureS
Favorite
8:00 AM – 6:00 PM
CEST
(245) Benefit-Risk Assessment of Herbal Medicines Used During Pregnancy and Lactation: A Descriptive Study of Registered Herbal Medicines in Bulgaria
Favorite
8:00 AM – 6:00 PM
CEST
(246) Changes in the Use of Carbamazepine Before, During and After Pregnancy: A Nationwide Study in France between 2013 and 2021
Favorite
8:00 AM – 6:00 PM
CEST
(247) Characterization of Pregnancy in Women of Childbearing Potential with ASCVD or Likely Familial Hypercholesterolemia: US Claims Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(248) Cohort event monitoring of COVID-19 vaccine safety using patient-reported outcomes in pregnant women.
Favorite
8:00 AM – 6:00 PM
CEST
(249) Comparator Cohort Selection: a Review of Prospective Pregnancy Registries for Multiple Sclerosis (MS) Products
Favorite
8:00 AM – 6:00 PM
CEST
(250) Comparison of Diagnoses Code Profile and Major Congenital Malformation (MCM) Prevalence across US and EU MCM Classification Systems
Favorite
8:00 AM – 6:00 PM
CEST
(251) Comprehensive evaluation of algorithm demonstrates robust performance identifying pregnancy cases in VigiBase
Favorite
8:00 AM – 6:00 PM
CEST
(252) Covid19 Vaccination During Pregnancy: a Descriptive Study of Uptake and Safety for Mothers and Infants Using the Nationwide French National Health System
Favorite
8:00 AM – 6:00 PM
CEST
(253) COVID-19 vaccination rate among pregnant women in France: a nationwide study
Favorite
8:00 AM – 6:00 PM
CEST
(254) Development of a Pregnancy Cohort in Commercial Insurance Claims Data: Evaluation of Inpatient Versus Apparent Outpatient Deliveries
Favorite
8:00 AM – 6:00 PM
CEST
(255) Disparities in asthma severity and treatment during pregnancy: description of the Slone Birth Defects Study data
Favorite
8:00 AM – 6:00 PM
CEST
(256) Effect of Tumor Necrosis Factor Inhibitor Use During Pregnancy on Gestational Diabetes Mellitus Among Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(257) Effectiveness of Awareness/Recruitment Activities for Pregnancy Registries
Favorite
8:00 AM – 6:00 PM
CEST
(258) Enhanced pharmacovigilance reporting using PRIM: conditions to make it an alternative to traditional pregnancy registry
Favorite
8:00 AM – 6:00 PM
CEST
(259) Evaluating the Incidence and Burden of Gestational Diabetes in the United States: A Retrospective Study (2015-2022)
Favorite
8:00 AM – 6:00 PM
CEST
(260) Evaluation of Digital Data collection Methods in a Prospective Pregnancy Registry for a Migraine Product with Both Acute and Preventive Indications
Favorite
8:00 AM – 6:00 PM
CEST
(261) Exposure to antibiotics during pregnancy or early infancy and the risk of autoimmune disease in children: A nationwide cohort study with sibling matched analysis
Favorite
8:00 AM – 6:00 PM
CEST
(262) Exposure to potentially harmful drugs during pregnancy in women with rheumatoid arthritis – a German claims data analysis
Favorite
8:00 AM – 6:00 PM
CEST
(264) Fetal and Neonatal Alloimmune Thrombocytopenia: Systematic Literature Review and Challenges Encountered
Favorite
8:00 AM – 6:00 PM
CEST
(265) Finding the Forest in the TreeScan: A Big Data Driven Approach to Screening Drug Use in Pregnancy
Favorite
8:00 AM – 6:00 PM
CEST
(266) First trimester tetracycline use and risk of major congenital malformations: A cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(267) Frequency of diagnosis codes for infant outcomes appearing on maternal health insurance claims
Favorite
8:00 AM – 6:00 PM
CEST
(268) Human Breastmilk Microbiome in Individuals with Hypothyroidism Treated with Levothyroxine Compared to Healthy Controls
Favorite
8:00 AM – 6:00 PM
CEST
(269) Identification of Maternal Characteristics, Pregnancy Characteristics and Pregnancy Outcomes through Linked Maternal and Infant Databases in Brazil
Favorite
8:00 AM – 6:00 PM
CEST
(270) Impacts of Dobbs Decision and COVID-19 on Abortion-related Trends within TriNetX Electronic Medical Record Data
Favorite
8:00 AM – 6:00 PM
CEST
(271) Improving Access to HIV-Related Healthcare, including Treatment and Pre-Exposure Prophylaxis (PrEP) in Zimbabwe Among Young Mothers Living with HIV
Favorite
8:00 AM – 6:00 PM
CEST
(272) Incidence of pregnancy among publicly and commercially insured childbearing-age women with warfarin treatment
Favorite
8:00 AM – 6:00 PM
CEST
(273) Is Hypothyroidism in Pregnancy Overtreated? A Retrospective Cohort Study from Bulgaria
Favorite
8:00 AM – 6:00 PM
CEST
(274) Language and racial disparities in initial COVID-19 vaccination during pregnancy
Favorite
8:00 AM – 6:00 PM
CEST
(275) Linkage of Mother and Infant Records using Commercial Claims Data within the Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative
Favorite
8:00 AM – 6:00 PM
CEST
(276) Linkage of Pregnancies and Infants to Potential Male Parents in a Health Insurance Claims Database
Favorite
8:00 AM – 6:00 PM
CEST
(277) Lower Rates of Initiation of Breastfeeding and Exclusive breastfeeding in Women Treated with Chronically Used Anti-inflammatory Medications
Favorite
8:00 AM – 6:00 PM
CEST
(278) Maternal and Infant Outcomes Following Infliximab Exposure During Pregnancy
Favorite
8:00 AM – 6:00 PM
CEST
(279) Maternal outcomes in women receiving COVID-19 vaccination during pregnancy compared with influenza vaccines in spontaneous reporting databases
Favorite
8:00 AM – 6:00 PM
CEST
(280) Miscarriage Preventing Herbal Medicines and the Risk of Birth Defects: A Population-Based Cohort Study of 195,824 Pregnancies
Favorite
8:00 AM – 6:00 PM
CEST
(281) Neonatal Intensive Care Unit Services among Commercially Insured Infants in the United States, 2016 – 2023
Favorite
8:00 AM – 6:00 PM
CEST
(282) Opioid Analgesic and Antidepressant Use During Pregnancy and the Risk of Spontaneous Preterm Birth: A Nested Case-Control Study
Favorite
8:00 AM – 6:00 PM
CEST
(283) Opioid Toxicity in the Year After Pregnancy Among Women with Disabilities
Favorite
8:00 AM – 6:00 PM
CEST
(284) Oral Antihypertensives in Hypertensive Pregnancy and the Association with Fetal Growth: a Population-Based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(285) Outcome-Anchored Cohorts to Prevent Pregnancy Study Pitfalls: A Conceptual Approach for Preventing Bias in Post-Approval Pregnancy Safety Studies
Favorite
8:00 AM – 6:00 PM
CEST
(287) Paternal exposure to valproate and the risk of Neuro-Developmental Disorders in offspring: a population-based cohort study in Denmark, Norway and Sweden
Favorite
8:00 AM – 6:00 PM
CEST
(288) Patterns of Prescribed and Dispensed Medicines among Non-Hospitalized Pregnant women with COVID-19: a Prospective Meta-analysis pooling findings from Healthcare Databases in Europe and North America
Favorite
8:00 AM – 6:00 PM
CEST
(289) Patterns of prescribing antihypertensive medications during pregnancy in the UK
Favorite
8:00 AM – 6:00 PM
CEST
(290) Periconceptional Oral Contraceptive Use and the Risk of Spontaneous Abortion: Results From the PRIDE Study.
Favorite
8:00 AM – 6:00 PM
CEST
(291) Postpartum Treatment Initiation among Pregnancies Diagnosed with Hepatitis C between 2016-2021 using the United States Commercial Claims Data
Favorite
8:00 AM – 6:00 PM
CEST
(292) Prediction of Hemolytic Disease of the Fetus and Newborn in neonates from alloimmunized pregnancies
Favorite
8:00 AM – 6:00 PM
CEST
(293) Predictors for correct vitamin D intake among pregnant women in the Netherlands
Favorite
8:00 AM – 6:00 PM
CEST
(294) Pregnancies and prescription drug use during pregnancy in women of childbearing potential with chronic spontaneous urticaria in the United States – A descriptive analysis
Favorite
8:00 AM – 6:00 PM
CEST
(295) Pregnancies with Unknown Outcome in CPRD Aurum: Investigation Conducted as Part of the Feasibility Assessment for a Potential Non-Interventional Post-Authorization Safety Study.
Favorite
8:00 AM – 6:00 PM
CEST
(296) Pregnancy and infant outcomes in gestationally-diagnosed breast cancer: A pilot study in Finland and Norway from the IMI ConcePTION project
Favorite
8:00 AM – 6:00 PM
CEST
(297) Pregnancy and Pain Outcomes When Elagolix and Hormonal Contraceptives are Used Concomitantly: A Prospective Cohort Study Using a Health Insurance Claims Database
Favorite
8:00 AM – 6:00 PM
CEST
(298) Pregnancy Outcomes and Maternal Morbidity Using Administrative Claims Data in the US
Favorite
8:00 AM – 6:00 PM
CEST
(299) Pregnant persons' perceptions of RSV vaccination during pregnancy
Favorite
8:00 AM – 6:00 PM
CEST
(300) Prenatal exposure to antiseizure medications and neurodevelopmental disorders: Children population-based cohort from the Quebec Pregnancy/Child Cohort
Favorite
8:00 AM – 6:00 PM
CEST
(301) Prenatal Exposure to Gabapentin and the Risk of Autism Spectrum Disorder in Children
Favorite
8:00 AM – 6:00 PM
CEST
(302) Prenatal syphilis in the US: characterizing screening and treatment during pregnancy in publicly and commercially insured individuals
Favorite
8:00 AM – 6:00 PM
CEST
(303) Prevalence of major congenital malformations in France between 2010 and 2021: estimates among the 9 millions children and foetuses of the EPI-MERES register and relevance for perinatal pharmacoepidemiology
Favorite
8:00 AM – 6:00 PM
CEST
(304) Prevalence of medication use for COVID-19 treatment in pregnancy: a two-stage individual patient data meta-analysis combining international registries.
Favorite
8:00 AM – 6:00 PM
CEST
(305) Prevalence of Selected Health Conditions among Individuals with Childbearing Potential to Inform the Development of the Pregnancy Safety Study Framework
Favorite
8:00 AM – 6:00 PM
CEST
(306) Recreational drug use in Pregnancy: An observational study
Favorite
8:00 AM – 6:00 PM
CEST
(307) Replicating a Published Real-World Evidence Study to Analyze Maternal Delivery Complications Using Electronic Medical Records from Community Hospitals
Favorite
8:00 AM – 6:00 PM
CEST
(308) Reproductive safety of glucagon-like peptide 1 receptor agonists (GLP1-RA) after maternal exposure in early pregnancy: a comparative ENTIS cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(309) Retrospective Application of the FDA Preliminary Pregnancy Safety Studies Framework to an Ongoing Pregnancy-Related Commitment
Favorite
8:00 AM – 6:00 PM
CEST
(310) Risk of congenital ocular anomaly in EUROmediCAT: Assessment of the Potential Risk of Taking Medications during Pregnancy in Europe.
Favorite
8:00 AM – 6:00 PM
CEST
(311) Risk of Neonatal and Maternal Adverse Events of Oral Anti-hypertensive Medications Used in Pregnancy: Evidence Synthesis from a Disproportionality Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(312) Sources and Characteristics of Quantitative Human Pregnancy Safety Data in U.S. FDA Approved Product Labeling, 2015-2021
Favorite
8:00 AM – 6:00 PM
CEST
(313) Specific congenital anomalies associated with maternal Multiple Sclerosis: A ConcePTION European case-malformed control study
Favorite
8:00 AM – 6:00 PM
CEST
(314) The association between COVID-19 vaccination during pregnancy and neonatal health outcomes
Favorite
8:00 AM – 6:00 PM
CEST
(315) The BELpREG Registry on Perinatal Medication Exposure and Mother-Infant Outcomes: Preliminary Insights into this unique Pregnancy Cohort in Belgium
Favorite
8:00 AM – 6:00 PM
CEST
(316) The IMEDS Distributed Database Network and Pregnancy Studies
Favorite
8:00 AM – 6:00 PM
CEST
(317) The Impact of the Mother-Infant Linkage Process in US Health Insurance Claims Data on the Representativeness of the Infant Sample
Favorite
8:00 AM – 6:00 PM
CEST
(318) The occurrence of specific congenital anomalies associated with maternal Systemic Lupus Erythematosus: A ConcePTION Case-malformed control study in EUROmediCAT
Favorite
8:00 AM – 6:00 PM
CEST
(319) The PregVal Project. A Population-based Cohort to Assess Drug Use and Safety During Pregnancy.
Favorite
8:00 AM – 6:00 PM
CEST
(320) The Risk of Postpartum Depression Based on Attention-Deficit/Hyperactivity Disorder Medication Use During Pregnancy
Favorite
8:00 AM – 6:00 PM
CEST
(321) Uptake of prescription smoking cessation pharmacotherapies during pregnancy: a population-based utilisation study across Australia, New Zealand, Norway, and Sweden
Favorite
8:00 AM – 6:00 PM
CEST
(322) US Claims Adaptation of the European Concerted Action on Congenital Anomalies and Twins (EUROCAT) Guide 1.5 for Use in Pregnancy Studies
Favorite
8:00 AM – 6:00 PM
CEST
(323) Use of healthcare administrative claims data in observational studies of antirheumatic drug effects on pregnancy outcomes: a scoping review
Favorite
8:00 AM – 6:00 PM
CEST
(324) Use of migraine medications during pregnancy and among women of childbearing age
Favorite
8:00 AM – 6:00 PM
CEST
(325) Use of population-based real world data sources and disease specific registries to conduct post approval pregnancy safety studies for a biologic indicated for a complex, uncommon indication - challenges and opportunities
Favorite
8:00 AM – 6:00 PM
CEST
(326) Use of the novel antiviral PAXLOVID for COVID-19 during pregnancy: methodological considerations for defining the baseline period across treated and untreated comparator cohorts
Favorite
8:00 AM – 6:00 PM
CEST
(327) Use of Weight-Loss Medications Among Pregnant People in the Optum Research Database
Favorite
8:00 AM – 6:00 PM
CEST
(328) Using Claims and Electronic Health Records for Pregnancy Safety Studies: A Targeted Review of Validated Algorithms.
Favorite
8:00 AM – 6:00 PM
CEST
(329) Using Real-World Data to Quantify the Rate of Unintended Pregnancies and Specified Adverse Events in Women Prescribed Oral Levonorgestrel 30µg or Levonorgestrel Implant
Favorite
8:00 AM – 6:00 PM
CEST
(330) A Comparison of Natural Language Processing (NLP) vs Clinician Review for Identification of Myocarditis Cases Following Vaccination with mRNA-1273
Favorite
8:00 AM – 6:00 PM
CEST
(331) Applicability of Selected Brighton Collaboration Case Definitions in Prospective Hospital-Based Safety Surveillance for Covid-19 Vaccines, Addis Ababa, Ethiopia
Favorite
8:00 AM – 6:00 PM
CEST
(332) Associations Between the Latest Received Dose of mRNA COVID-19 Vaccine Product and Chronic or Other Types of Urticaria: Nationwide Registry-Based Cohort Study in Denmark
Favorite
8:00 AM – 6:00 PM
CEST
(333) Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in South Korea
Favorite
8:00 AM – 6:00 PM
CEST
(334) Comparative Seroprevalence Analysis of COVID-19 Vaccination Strategies: Insights from a Multicenter Study in Castilla-Leon, Spain
Favorite
8:00 AM – 6:00 PM
CEST
(335) COVID-19 and influenza vaccine co-administration among older U.S. adults
Favorite
8:00 AM – 6:00 PM
CEST
(336) Current Approaches in Post-Approval Vaccine Safety Studies Using Real-World Data: A Systematic Review of Published Literature
Favorite
8:00 AM – 6:00 PM
CEST
(337) Defining a Post-vaccine Myocarditis Cohort by Applying CDC Case Definition to Structured EHR and Claims Data as a Proxy for Case Adjudication
Favorite
8:00 AM – 6:00 PM
CEST
(338) Effectiveness Evaluation of the Additional Risk Minimisation Measures for Yellow Fever Vaccine in the United Kingdom: A Survey for Healthcare Professionals and Vaccinees
Favorite
8:00 AM – 6:00 PM
CEST
(339) Eighteen-month follow-up cohort study of post-vaccination COVID-19 myocarditis in France compared with other forms of myocarditis
Favorite
8:00 AM – 6:00 PM
CEST
(340) Epidemiology of Thrombotic Thrombocytopenia Syndrome before, during and post COVID-19 pandemic: English sentinel network cohort studies
Favorite
8:00 AM – 6:00 PM
CEST
(341) Evaluating impact of time-varying confounders in self-controlled risk interval analysis in a vaccine-safety cohort event monitoring-based simulation study
Favorite
8:00 AM – 6:00 PM
CEST
(342) Final Results from Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
Favorite
8:00 AM – 6:00 PM
CEST
(343) Healthcare utilization among SARS-CoV-2 mRNA vaccine-associated myocarditis cases: a matched retrospective cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(344) Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe
Favorite
8:00 AM – 6:00 PM
CEST
(345) Mapping Genetic and Molecular Contributions to Vaccine Adverse Reactions: a systematic review of observational studies
Favorite
8:00 AM – 6:00 PM
CEST
(346) Measuring Association of Acute Disseminated Encephalomyelitis and Transverse Myelitis following COVID-19 vaccination using a Self-Controlled Case Series Analysis of Real-World Linked Data
Favorite
8:00 AM – 6:00 PM
CEST
(347) Methodological considerations for the design and implementation of real-world vaccine-related studies in low- and middle-income countries
Favorite
8:00 AM – 6:00 PM
CEST
(348) Multimodal surveillance and the importance of enabling gender-based risk stratification capabilities in real world data
Favorite
8:00 AM – 6:00 PM
CEST
(349) Patient-level prognostic models for COVID-19 vaccine effectiveness and safety: a systematic review
Favorite
8:00 AM – 6:00 PM
CEST
(350) Predicting Recovery Status of COVID-19 Vaccinated Patients with Natural Language Processing Approaches
Favorite
8:00 AM – 6:00 PM
CEST
(351) Preliminary Findings from a Feasibility and Capacity Assessment of Truveta® Studio using Flu Vaccine as Example: A Near Real-Time Electronic Health Records Database with Potential to Monitor Post-Approval Vaccine Safety
Favorite
8:00 AM – 6:00 PM
CEST
(352) Quantifying Bias in COVID-19 Vaccine Effectiveness (VE) Estimates Due to Missing Information on Prior SARS-CoV-2 Infection: an Assessment Using Data from the European COVIDRIVE Study
Favorite
8:00 AM – 6:00 PM
CEST
(353) Rare adverse events of interest following vaccination: Strengths and weaknesses of a national data resource compared to the national sentinel network database
Favorite
8:00 AM – 6:00 PM
CEST
(354) Real-world Nuvaxovid COVID-19 vaccine safety profile after first 100,000 doses in Australia
Favorite
8:00 AM – 6:00 PM
CEST
(355) Relative effectiveness (rVE) of the high-dose vs. standard-dose influenza vaccines in the French National health data system (SNDS) for people aged 65+ living in community, obtained using two approaches based on the propensity score
Favorite
8:00 AM – 6:00 PM
CEST
(356) Risk of Encephalitis and Meningitis After COVID-19 Vaccination in South Korea: a Self-controlled Case Series Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(357) Risks of Cardiovascular Events Following COVID-19 Vaccination – Results From a Nationwide Cohort Study of 8 Million Swedish Adults
Favorite
8:00 AM – 6:00 PM
CEST
(358) Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 months and Older in the United States
Favorite
8:00 AM – 6:00 PM
CEST
(359) Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European Healthcare Data Sources: Methods and Results of the Second Study Feasibility Assessment
Favorite
8:00 AM – 6:00 PM
CEST
(360) Feasibility of Prospective Real-World Studies to Fulfill Regulatory Commitments and Requirements in Oncology within the United States (US)
Favorite
8:00 AM – 6:00 PM
CEST
(361) Sex Inequity in Access to Safe Vaccination: A Sex Disaggregated Comparative Analysis of Vaccine Safety Surveillance Reports and Social Media Vaccine-Related Health Mentions.
Favorite
8:00 AM – 6:00 PM
CEST
(362) Stroke Risk Following Receipt of High-Dose/Adjuvanted Influenza Vaccinations Among U.S. Adults Aged ≥65 Years; 2016-2019
Favorite
8:00 AM – 6:00 PM
CEST
(363) The Association between COVID-19 Vaccines and Menstrual Disorders: A Systematic Review.
Favorite
8:00 AM – 6:00 PM
CEST
(364) The Importance of Standardization in Observed-to-Expected Analysis: Using COVID-19 Vaccine Adverse Event as an Example.
Favorite
8:00 AM – 6:00 PM
CEST
(365) Tokenization and linkage of state vaccine registry data to improve determination of COVID-19 vaccination status in a large administrative claims database
Favorite
8:00 AM – 6:00 PM
CEST
(366) Trends of COVID-19 Vaccine Adverse Event Following Immunization (AEFI): A One-year Retrospective Review Using the Passive Surveillance Data in the Nigerian National Database (Vigiflow).
Favorite
8:00 AM – 6:00 PM
CEST
(367) VAC4EU study to identify risk factors and characterize the clinical course of myocarditis/pericarditis following mRNA-1273 vaccination in four European countries: first descriptive analyses
Favorite
8:00 AM – 6:00 PM
CEST
(368) Vaccine Cohort Event Monitoring: Enhancement of Safety Data Collection
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT01) Variation in the time to complete the primary COVID-19 vaccine series by race, ethnicity, and geography among older US adults
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT02) A prospective cohort study of risk factors associated with prostate cancer incidence in predominantly low-income Black Americans
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT03) Advancing Health Equity in Europe: A Framework of Diversity and Fairness in Pharmacoepidemiologic Research
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT04) Comparing the Risk of Metoprolol-Related Adverse Drug Events Between Women and Men with Heart Failure Using Effectiveness Outcomes as a Proxy: a Population-Based Cohort Study using CPRD
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT05) Interpreting Effect Estimates Across Racial and Ethnic Categories in Propensity Score-Based Analyses: An Application in US Medicare Beneficiaries Initiating Antidiabetic Medications
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT06) Racial diversity and multimodal safety assessments: limitations of spontaneous reports data and the importance of advancing race-based risk stratification capabilities in real world data
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT07) What we owe to patients: A systematic literature review into reporting of potential biases in clinical decision support tools that use AI to personalise care in viral hepatitis
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT08) Enhancing Early Detection of Medical Device Safety Signals: A Case Study of Implantable Cardioverter Defibrillator Leads
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT09) Hospital readmissions among patients with atrial fibrillation undergoing catheter ablation using ThermoCool SmartTouch/ThermoCool SmartTouch SF Catheter with CARTO 3 System versus TactiCath Catheter with EnSite System
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT10) Impact of longitudinal data completeness on risk adjustment and outcome evaluation in hospitals database
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT11) Using Electronic Health Record Data and Neural Network to Predict 90-day Readmission after Peripheral Vascular Intervention: Can it Match and Augment the Capacity of Clinical Registry?
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT12) Racial and Ethnic Disparities in Robot-Assisted Radical Prostatectomy: Physician-level Mechanisms
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT13) Does an additional gold or silver alloy provide any benefit over copper-only intrauterine devices? Insights from the EURAS-LCS12 study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT14) All Enabling Technology is not created equal: comparing outcomes of computer assisted fluoroscopic hip navigation versus robotic-assisted total hip arthroplasty
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT15) Transcatheter and Surgical Aortic Valve Implantation in the Management of Aortic Stenosis between 2010 and 2022: a French Nationwide Study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT16) Paternal metformin use before pregnancy and risk of congenital malformations: a cross-national cohort study in Norway and Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT17) Trajectories for migraine medication in pregnancy and neurodevelopmental outcomes in offspring - a nationwide registry-based study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT18) Concomitant Use of Antidepressants and Benzodiazepines During Pregnancy and Associated Risk of Congenital Malformations in Offspring: Population Based Cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT19) Estimating the Risk of Gestational Diabetes Mellitus Associated With Antidepressant Continuation During Pregnancy Using a Treatment Decision Study Design
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT20) Prevalence and treatment of chronic hypertension during pregnancy in a U.S. cohort, 2008-2021
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT21) Changes in adverse event reporting of neurodevelopmental disorders after maternal valproate exposure, following a major scientific publication and regulatory decisions, a contribution of the ConcePTION project
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT22) Associations between Dose of Prescribed Opioid Analgesic Exposure During Pregnancy and Adverse Birth Outcomes and Early Mortality: A Population-Based Study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT23) Evaluating performance and methodologies of machine learning and conventional pharmacoepidemiologic modeling to identify pregnant individuals at risk of giving birth to children with major congenital malformations
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT24) Data Mining for Adverse Events of Montelukast in Children and Adolescents: A Tree-Based Scan Statistics Analysis of Swedish Nationwide Data
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT25) Proton Pump Inhibitors Use and Risk of Inflammatory Bowel Disease in Children: A Population-based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT26) Association between childhood exposure to nuclear medicine and the risk of malignancy: sibling control and population-based cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT27) Severe Cutaneous Adverse Reactions Associated with Antibiotics in Pediatric Patients
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT28) How far can we go with Federated Meta-Analytic Approaches in Rare Diseases and Special Populations: A Case Example in Pediatric Pulmonary Arterial Hypertension for Regulatory Purposes
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT29) Trends in the prescribing of controlled substances to children and young adults enrolled in Medicaid, 2001-2019
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT30) Pediatric Utilization of New Molecular Entities (NMEs): A Summary of Early Post-marketing Uptake in the Sentinel Distributed Database
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT31) Real-world Research on Drug Safety Based on Quantitative Structure-Activity Relationship: A Case Study on Pediatric Drug-Induced Immune Thrombocytopenia
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT32) Important Tool in our Rare Disease Toolbox: Hybrid Retrospective-Prospective Natural History Studies Serve Well as External Comparators for Rare Disease Studies
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT33) Natural history of dermatomyositis and polymyositis in adults and paediatric populations: a network cohort study part of DARWIN EU®
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT34) Characteristics of Patients with ATTR Amyloidosis and Methodological Approaches for Establishing Clinical Subtype in the Netherlands
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT35) Leverage of an EHR Database to Estimate Prevalence and Incidence of Lymphatic Malformations (a Rare Disease) in the UK
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT36) Assessing Clinical Evidence for the Incorporation of Technologies in Ultra-rare Diseases in Brazil: A Decade of CONITEC Reports
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT37) Identifying women of childbearing age with Multiple Sclerosis in six European healthcare data sources - A contribution from the IMI-ConcePTION project
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT38) Estimating period prevalence: comparing methods to describe a rare disease population
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT39) Building Patient Journeys for Prader-Willi Syndrome Patients: Insights from Electronic Health Records Through Natural Language Processing
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT40) Incident benzodiazepine and Z-drug use and subsequent risk of serious infections
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT41) Current Applications of Machine Learning for Causal Inference in Healthcare Research using Observational Data
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT42) Signal Detection using Real World Data - Anticipating Serious Outcomes in Cancer Patients through Thresholds Ranges derived from US-based Claims Data
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT43) Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: a nationwide retrospective cohort study with a non-inferiority primary objective.
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT44) Real-World Trends in SARS-CoV-2 Antibody Levels and Their Link to Subsequent COVID-19 in the United States
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT45) High-throughput sequence symmetry analysis to detect Beta-Blocker induced prescribing cascades
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT46) Tree-based Scan Statistics to Identify Drug Repurposing Signals: a Test Case using Sodium-Glucose Cotransporter-2 Inhibitors
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT47) The Effect of Sodium Glucose Cotransporter-2 Inhibitors on HbA1c Variability and Acute Kidney Injury: A Causal Mediation Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT48) Effects of Sequential vs Single Pneumococcal Vaccination on Cardiovascular Diseases among Older Adults: a Population-based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT49) Quality of and methodological heterogeneity in COVID-19 Vaccine safety studies – Case study of the myocarditis safety signal
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT50) Risk of New-Onset Seizures Following Immunization against COVID-19 in South Korea: A Self-Controlled Case-Series Study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT51) Signal Monitoring for Adverse Events Following Immunization with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT52) Immunomodulatory treatment and immune responses to COVID-19 booster shots in patients with autoimmune rheumatic diseases: Results from the Covid-19 VaccinE Response in Rheumatology patients (COVER) study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT53) Initial Observations on RSV Vaccine Use in Pregnant Patients
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT54) Special Populations Addressed in Vaccines Approved via the European Medicines Agency
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT55) Use of the Shingrix Vaccine Among Patients with Inflammatory Arthritis and Risk of Cardiovascular Events Following Herpes Zoster
Favorite
